Recent Comments

    PCSK9 (proprotein convertase subtilisin/kexin type 9) tagged posts

    Molecular Therapy set to Protect at-risk Patients against Heart Attack and Stroke

    April 1, 2017, Categories  Health/Medical, Biology/Biotechnology

    Changes in LDL Cholesterol Levels. The change in LDL cholesterol level from baseline to day 180 is shown for each patient randomly assigned to the two-dose placebo group (61 patients) (Panel A) and the two-dose 300-mg inclisiran group (59 patients) (Panel B); the changes from baseline to day 240 are also shown for the two-dose 300-mg inclisiran group (59 patients) (Panel C). Dashed lines represent LDL cholesterol reductions of 39 mg per deciliter and 78 mg per deciliter. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586.

    Changes in LDL Cholesterol Levels. The change in LDL cholesterol level from baseline to day 180 is shown for each patient randomly assigned to the two-dose placebo group (61 patients) (Panel A) and the 2-dose 300-mg inclisiran group (59 patients) (Panel B); the changes from baseline to day 240 are also shown for the two-dose 300-mg inclisiran group (59 patients) (Panel C). Dashed lines represent LDL cholesterol reductions of 39 mg per deciliter and 78 mg per deciliter. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586.

    siRNA treatment inactivates harmful protein...

    Read More